改善病情抗风湿药对类风湿关节炎患者血脂及心血管疾病风险的影响现状  

Effect of antirheumatic drugs on blood lipid and cardiovascular disease risk in patients with rheumatoid arthritis

作　　者：黄红[1] 耿研[1] 樊勇[1] 张卓莉[1] HUANG Hong;GENG Yan;FAN Yong;ZHANG Zhuo-li(Department of Rheumatology and Immunology,PekinggUniversity First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院风湿免疫科,北京100034

出　　处：《中国临床药理学杂志》2023年第17期2566-2570,共5页The Chinese Journal of Clinical Pharmacology

摘　　要：类风湿关节炎(RA)是一种常见的系统性自身免疫病,可发生于任何年龄,其治疗主要依赖于改善病情抗风湿药(DMARDs)。近年来,随着不同种类DMARDs的广泛应用,人们发现这类药物或对血脂代谢及心血管疾病会产生不同程度的影响。随着疗效与安全性研究证据的积累,人们开始越来越多地关注上述影响。本文将有关DMARDs对RA患者血脂谱及心血管疾病影响的研究进行总结,旨在为国内风湿免疫科医师的临床实践提供科学的依据。Rheumatoid arthritis(RA)is a common systemic autoimmune disease that can occur at any age.The treatment of RA mainly depends on the disease modified anti-rheumatic drugs(DMARDs).With the launch and availability of different types of DMARDs,their various effects on lipid metabolism and cardiovascular diseases have been noticed.Moreover,these effects have attracted increasing attention and have been often reported with accumulating evidence.In this article,we summarize the research of DMARDs on lipid profiles and cardiovascular diseases in RA patients to help Chinese rheumatologists with better clinical practice.

关 键 词：类风湿关节炎 改善病情抗风湿药 血脂谱 心血管疾病 

分 类 号：R97[医药卫生—药品]